Core Insights - ZEISS Medical Technology has received CE mark approval for its innovative AI clinical support tool, CIRRUS® PathFinder™, which enhances decision-making and workflow efficiency in OCT interpretation [2][4] - The tool utilizes proprietary deep learning algorithms to automatically identify abnormal macular OCT B-scans, improving diagnostic capabilities and patient care [2][5] - The integration of AI decision support allows clinicians to assess hundreds of scans in real-time, significantly enhancing workflow and patient outcomes [7] Company Overview - Carl Zeiss Meditec AG is a leading medical technology company focused on innovative technologies and solutions to improve patient care, with a revenue of €2,066.1 million in fiscal year 2023/24 [14][15] - The company employs approximately 5,730 people globally, with a significant presence in the USA, Japan, Spain, and France [15] - ZEISS is committed to developing digital diagnostic tools that streamline workflows, lower costs, and enhance patient experiences [4][10] Product Features - CIRRUS PathFinder™ includes AI-enhanced OCTA image quality, multi-layer segmentation, and improved visualization of vascular structures, which collectively enhance diagnostic capabilities [8][10] - The software update features a Reference Database that is three times larger than its predecessor, along with enhanced cybersecurity measures [10][9] - The AI decision support tool is designed to work seamlessly within the clinician's existing workflow, eliminating the need for third-party data analysis [7][9]